Edition:
India

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

22.25USD
20 Feb 2018
Change (% chg)

-- (--)
Prev Close
$22.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
351,731
52-wk High
$23.90
52-wk Low
$3.65

Latest Key Developments (Source: Significant Developments)

Sangamo And Pfizer Announce Collaboration For Development Of Zinc Finger Protein Gene Therapy For Als
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Pfizer Inc ::SANGAMO AND PFIZER ANNOUNCE COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS.SANGAMO THERAPEUTICS​ - CO, ‍PFIZER ANNOUNCED COLLABORATION FOR DEVELOPMENT OF ZINC FINGER PROTEIN GENE THERAPY FOR ALS.SANGAMO THERAPEUTICS INC - UNDER TERMS OF COLLABORATION AGREEMENT, SANGAMO WILL RECEIVE A $12 MILLION UPFRONT PAYMENT FROM PFIZER.SANGAMO THERAPEUTICS INC - UNDER AGREEMENT, CO ‍WILL BE RESPONSIBLE FOR DEVELOPMENT OF ZFP-TF CANDIDATES​.SANGAMO - UNDER TERMS ELIGIBLE TO RECEIVE POTENTIAL DEVELOPMENT & COMMERCIAL MILESTONE PAYMENTS UP TO $150 MILLION, TIERED ROYALTIES ON NET SALES.SANGAMO - UNDER DEAL,‍PFIZER OPERATIONALLY,FINANCIALLY RESPONSIBLE FOR RESEARCH,DEVELOPMENT,COMMERCIALIZATION FOR C9ORF72 ZFP-TF,RESULTING PRODUCTS.  Full Article

Sangamo Says European Medicines Agency Recommends Orphan Medicinal Product Designation For Investigational Genome Editing Treatments
Friday, 8 Dec 2017 

Dec 7 (Reuters) - Sangamo Therapeutics Inc ::SANGAMO ANNOUNCES EUROPEAN MEDICINES AGENCY RECOMMENDATION OF ORPHAN MEDICINAL PRODUCT DESIGNATION FOR INVESTIGATIONAL GENOME EDITING TREATMENTS FOR MPS I AND MPS II.SANGAMO THERAPEUTICS - PHASE 1/2 CLINICAL TRIALS FOR PROGRAMS, EVALUATING SB-318 & SB-913 IN ADULTS WITH MPS I AND MPS II, ARE ENROLLING SUBJECTS.  Full Article

Sangamo says patient received therapy intended to precisely edit DNA of cells directly inside body​
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Sangamo Therapeutics Inc -:Sangamo announces treatment of first patient in landmark phase 1/2 clinical trial evaluating in vivo genome editing for MPS II.‍A patient has received a therapy intended to precisely edit DNA of cells directly inside body​.  Full Article

Sangamo Therapeutics posts Q3 loss per share $0.15
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Sangamo Therapeutics Inc :Sangamo Therapeutics reports third quarter 2017 financial results.Q3 revenue $11.8 million versus I/B/E/S view $10.4 million.Q3 loss per share $0.15.Sees FY 2017 revenue $30 million to $40 million.Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Sangamo Therapeutics Inc - ‍company expects that revenues will be in range of $30 million to $40 million in 2017​.FY2017 revenue view $33.2 million -- Thomson Reuters I/B/E/S.  Full Article

Sangamo Biosciences receives orphan drug designation from the FDA for sb-fix, the first application of therapeutic in vivo genome editing
Tuesday, 6 Sep 2016 

Sangamo Biosciences Inc : Fix, the first application of therapeutic in vivo genome editing .Sangamo Biosciences Inc Says Expects To Initiate A Phase 1/2 Clinical Study (Sb fix-1501) in adult subjects with disease in 2016.  Full Article

Sangamo Bio sees FY 2016 revenue $12 million to $17 million
Thursday, 4 Aug 2016 

Sangamo Biosciences Inc : Sangamo biosciences reports second quarter 2016 financial results . Q2 revenue view $5.4 million -- Thomson Reuters I/B/E/S . Sees fy 2016 revenue $12 million to $17 million . Q2 revenue $3.7 million versus $8.4 million . Q2 loss per share $0.38 . Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S .Sangamo expects that operating expenses will be in range of $85 million to $95 million for 2016.  Full Article

Sangamo BioSciences announces FDA clearance
Monday, 20 Jun 2016 

Sangamo BioSciences Inc : To initiate SB-913-1602 clinical study for MPS II in second half of 2016 .Announces FDA clearance of investigational new drug application for ZFN-mediated genome editing treatment of MPS II.  Full Article

Sangamo Biosciences says CEO Edward Lanphier to retire
Wednesday, 1 Jun 2016 

Sangamo Biosciences Inc : Sangamo Biosciences announces retirement of Edward Lanphier as president and CEO; Sandy Macrae named as successor . Current chairman William Ringo to remain on board .Lanphier to assume chairmanship of board of directors.  Full Article

Sangamo BioSciences Inc reaffirms FY 2016 revenue guidance
Tuesday, 3 May 2016 

Sangamo BioSciences Inc:Expects that revenues will be in the range of $20 million to $25 million in FY 2016, inclusive of research funding from existing collaborations.  Full Article

BRIEF-Sangamo Therapeutics Appoints Heather Turner As Senior Vice President

* SANGAMO THERAPEUTICS ANNOUNCES APPOINTMENT OF HEATHER D. TURNER AS SENIOR VICE PRESIDENT AND GENERAL COUNSEL Source text for Eikon: Further company coverage: